Possible roles of sestrin2 in multiple sclerosis and its relationships with clinical outcomes Possíveis papéis da sestrina2 na esclerose múltipla e suas relações com resultados clínicos

Creative Commons License

Odabas F. O., Uca A. U., Akdag T., Demi̇Rdögen F., Altas M., Tokgoz O. S.

Arquivos de Neuro-Psiquiatria, cilt.80, sa.4, ss.399-404, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 80 Sayı: 4
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1590/0004-282x-anp-2021-0202
  • Dergi Adı: Arquivos de Neuro-Psiquiatria
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, MEDLINE, Psycinfo, Veterinary Science Database, Directory of Open Access Journals
  • Sayfa Sayıları: ss.399-404
  • Anahtar Kelimeler: Multiple Sclerosis, Sestrins, Apoptosis, Biomarkers, Inflammation, Oxidative Stress
  • Erzincan Binali Yıldırım Üniversitesi Adresli: Evet

Özet

© 2022 Associacao Arquivos de Neuro-Psiquiatria. All rights reserved.Background: Characterized by demyelination, inflammation and axonal damage, multiple sclerosis (MS) is one of the most common disorders of central nervous system led by the immune system. There is an urgent and obvious need for biomarkers for the diagnosis and follow-up of MS. Objective: To investigate serum levels of sestrin2 (SESN2), a protein that responds to acute stress, in MS patients. Methods: A total of 85 participants, 40 patients diagnosed previously with relapsing-remitting MS and 45 healthy controls, were included. Serum SESN2 parameters were investigated in blood samples drawn from each participant in the patient and control groups. Results: SESN2 levels were significantly lower in MS patients than in controls (z: -3.06; p=0.002). In the ROC analysis of SESN2, the predictive level for MS was 2.36 ng/mL [sensitivity, 72.50%; specificity, 55.56%; p=0.002; area under the curve (AUC)=0.693]. For the cut-off value in both groups, SESN2 was an independent predictor for MS [Exp (B)=3.977, 95% confidence interval (95%CI) 1.507–10.494 and p=0.013]. Conclusions: The decreased expression of SESN2 may play a role in MS pathogenesis, and SESN2 could be used as a biomarker for MS and as immunotherapeutic agent to treat MS.